Nipro Medical Corporation has announced the commercial launch of its Surdial Dx haemodialysis system—designed to create an optimal dialysis treatment experience for patients and clinicians—in the USA.
Manufactured in Japan, the system draws from more than 35 years of expertise in renal device innovation at Nipro’s parent company, Nipro Corporation, according to a press release.
Surdial Dx was developed with key input from clinicians to offer patient-focused features for optimal performance, efficiency, and ergonomics, the release adds. With its soft launch coming in late 2021, the company’s US team is now rolling out the full-scale commercial release of Surdial Dx to dialysis clinics across the country.
With local manufacturing in Pennsylvania, and supported by a global network of 60-plus production sites, Nipro is “well-positioned to supply a full-scale renal portfolio to Americans—coupling Surdial Dx together with its line of dialysers, blood tubing sets, AVF [arteriovenous fistula] needles, concentrates, solutions, vascular access management, and other renal accessories”, the press release also notes.